Marfan's syndrome cost-effectiveness of therapy

Editors-In-Chief: William James Gibson, C. Michael Gibson, M.S., M.D.

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [1] ; Assistant Editor-In-Chief: Cassandra Abueg, M.P.H. [2]

Overview

Cost Effectiveness

Currently, laboratories offer complete sequencing of the 65 exon FBN1 gene for approximately $1700.00 ^[1]. The high costs of these diagnostics have delayed the widespread use of molecular diagnostics in the approach to patients suspected of Marfan syndrome. Increasingly less expensive sequencing technologies promise to increase reliance on individual genetic data for diagnosis in the future.

References

↑ (Accessed November 22, 2010, at http://www.bcm.edu/pediatrics/index.cfm?Realm=99992426&This_Template=FBN1.)

Template:WH Template:WS

[1] (Accessed November 22, 2010, at http://www.bcm.edu/pediatrics/index.cfm?Realm=99992426&This_Template=FBN1.)

[1]